Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial

Li Zhang(Jinan Stomatological Hospital), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Baohui Han(Shanghai Jiao Tong University), Ying Cheng(Jilin Province Tumor Hospital), Nobuya Hayashi(AstraZeneca (United Kingdom)), Jie Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Shucai Zhang(Northeastern University), Xiangwei Zhang, Cheng Huang(Army Medical University), Xiangqun Song(Tumor Hospital of Guangxi Medical University), Yunpeng Liu(Shenyang Institute of Automation), Xiaoqing Liu(Chinese PLA General Hospital), Shujun Yang(Henan Cancer Hospital), Shun Lü(Shanghai Jiao Tong University), Shenglin Ma(Hangzhou Medical College), Caicun Zhou(Tongji University)
The Lancet Oncology
April 16, 2012
10.1016/s1470-2045(12)70117-1
Cited by 228

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k